Oncology Central

Clinical significance of FGFR1 gene amplification in lung cancer patients

0

Background: Lung cancer is the leading cause of cancer related death worldwide. Molecular targeted therapies are routinely used for pulmonary adenocarcinomas, harboring therapeutically tractable genomic aberrations such as EGFR mutations, ALK and ROS1 fusions. Comparable therapeutic options are still missing for squamous and small-cell lung cancer.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.